Comparison of BCR-ABL1 quantification in peripheral blood and bone marrow using an International Scale-standardized assay for assessment of deep molecular …
G Greiner, F Ratzinger, M Gurbisz… - Clinical Chemistry and …, 2020 - degruyter.com
Background Monitoring of molecular response (MR) using quantitative polymerase chain
reaction (PCR) for BCR-ABL1 is a pivotal tool for guiding tyrosine kinase inhibitor therapy …
reaction (PCR) for BCR-ABL1 is a pivotal tool for guiding tyrosine kinase inhibitor therapy …
Comparison of BCR-ABL1 quantification in peripheral blood and bone marrow using an International Scale-standardized assay for assessment of deep molecular …
G Greiner, F Ratzinger, M Gurbisz… - Clinical Chemistry …, 2020 - europepmc.org
Background Monitoring of molecular response (MR) using quantitative polymerase chain
reaction (PCR) for BCR-ABL1 is a pivotal tool for guiding tyrosine kinase inhibitor therapy …
reaction (PCR) for BCR-ABL1 is a pivotal tool for guiding tyrosine kinase inhibitor therapy …
Comparison of BCR-ABL1 quantification in peripheral blood and bone marrow using an International Scale-standardized assay for assessment of deep molecular …
G Greiner, F Ratzinger, M Gurbisz, N Witzeneder… - Clin Chem Lab …, 2020 - degruyter.com
Background: Monitoring of molecular response (MR) using quantitative polymerase chain
reaction (PCR) for BCR-ABL1 is a pivotal tool for guiding tyrosine kinase inhibitor therapy …
reaction (PCR) for BCR-ABL1 is a pivotal tool for guiding tyrosine kinase inhibitor therapy …
Comparison of BCR-ABL1 quantification in peripheral blood and bone marrow using an International Scale-standardized assay for assessment of deep molecular …
G Greiner, F Ratzinger, M Gurbisz… - Clinical Chemistry & …, 2020 - search.ebscohost.com
Background: Monitoring of molecular response (MR) using quantitative polymerase chain
reaction (PCR) for BCR-ABL1 is a pivotal tool for guiding tyrosine kinase inhibitor therapy …
reaction (PCR) for BCR-ABL1 is a pivotal tool for guiding tyrosine kinase inhibitor therapy …
Comparison of BCR-ABL1 quantification in peripheral blood and bone marrow using an International Scale-standardized assay for assessment of deep molecular …
G Greiner, F Ratzinger, M Gurbisz… - Clinical chemistry …, 2020 - pubmed.ncbi.nlm.nih.gov
Background Monitoring of molecular response (MR) using quantitative polymerase chain
reaction (PCR) for BCR-ABL1 is a pivotal tool for guiding tyrosine kinase inhibitor therapy …
reaction (PCR) for BCR-ABL1 is a pivotal tool for guiding tyrosine kinase inhibitor therapy …
Comparison of BCR-ABL1 quantification in peripheral blood and bone marrow using an International Scale-standardized assay for assessment of deep molecular …
G Greiner, F Ratzinger, M Gurbisz… - Clinical Chemistry and …, 2020 - hero.epa.gov
Background Monitoring of molecular response (MR) using quantitative polymerase chain
reaction (PCR) for BCR-ABL1 is a pivotal tool for guiding tyrosine kinase inhibitor therapy …
reaction (PCR) for BCR-ABL1 is a pivotal tool for guiding tyrosine kinase inhibitor therapy …
[HTML][HTML] Comparison of BCR-ABL1 quantification in peripheral blood and bone marrow using an International Scale-standardized assay for assessment of deep …
G Greiner, F Ratzinger, M Gurbisz… - Clinical chemistry and …, 2020 - ncbi.nlm.nih.gov
Background Monitoring of molecular response (MR) using quantitative polymerase chain
reaction (PCR) for BCR-ABL1 is a pivotal tool for guiding tyrosine kinase inhibitor therapy …
reaction (PCR) for BCR-ABL1 is a pivotal tool for guiding tyrosine kinase inhibitor therapy …
Comparison of BCR-ABL1 quantification in peripheral blood and bone marrow using an International Scale-standardized assay for assessment of deep molecular …
G Greiner, F Ratzinger, M Gurbisz… - Clinical Chemistry …, 2020 - europepmc.org
Background Monitoring of molecular response (MR) using quantitative polymerase chain
reaction (PCR) for BCR-ABL1 is a pivotal tool for guiding tyrosine kinase inhibitor therapy …
reaction (PCR) for BCR-ABL1 is a pivotal tool for guiding tyrosine kinase inhibitor therapy …